On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion.
A narrow question about Tirzepatide in type 2 diabetes, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer.
One question, stated units, stated method, and what I have already ruled out.
This follows the opening post rather than contradicting it.
Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.
The uncertainty is in the assumption, not in the calculation.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
I have said this before in a thread nobody could find, so it is worth repeating.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
This is the sort of thing the wiki should carry and currently does not.
Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme. Individual reports here vary in both directions, which is what you would expect from a between-person difference rather than a between-drug one.
Picking up post #6: that is the part I would want checked first.
Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.
I would want to see it done twice before believing it once.
Thank you for the correction. I would rather find out here than later.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.
Two sources, same conclusion, and I could not rule out that one copied the other.
Tirzepatide in type 2 diabetes: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.
This is the version I would want a new member to read first.
Post #11 is right about the mechanism and I think understates the practical bit.
What I want from this Tirzepatide in type 2 diabetes thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
Quietly grateful for the plain phrasing. Not every thread gets that.
I had written a reply contradicting post #15 and deleted it. Here is what survived.
I have been on both sides of the Tirzepatide in type 2 diabetes argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
Confirming post #15 from a second method, which matters more than confirming it from a second person.
One caution on Tirzepatide in type 2 diabetes: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Post #15 put the caveat in the right place and I want to underline it.
SURPASS-2's comparator choice is the criticism that survives. Semaglutide 1.0 mg was the licensed diabetes dose at the time and it was not the highest dose available in the class, so the trial answers a narrower question than the headline implies.
The general answer and the answer for your case may diverge here.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.
I disagree with the framing of Tirzepatide in type 2 diabetes above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
The titration schedule has more steps than semaglutide's, which reflects the finer gradation used in the clinical programme rather than a pharmacological requirement for smaller steps.
The honest answer is that it depends, and here is what it depends on.
Building on post #20 rather than restating it.
Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.
That has held every time I have looked, which is not the same as always.
Post #22 put the caveat in the right place and I want to underline it.
Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.
Anyone who has looked at this more carefully, please correct the record.
Adding the measurement that post #24 says would settle it.
Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.
I looked this up rather than remembered it, which is the right order.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
That is what I would do. It may not be what is correct.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
This is the first time the answer has come with its own limits attached. Appreciated.
Post #27 answers the question as asked. The question underneath it is different.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
I read post #26 twice before replying, because I had assumed the opposite.
The titration schedule has more steps than semaglutide's, which reflects the finer gradation used in the clinical programme rather than a pharmacological requirement for smaller steps.
That has been true for the cases I have seen and I have not seen many.